Proposed Investment and collaboration, as contemplated by a letter of intent, aims to evaluate the feasibility of providing critical power infrastructure with advanced fuel maintenance solutions to an estimated $300 billion market of data centers in 2026
NYSE: MMA to Relaunch MixedMartialArts.com With Original Fight Week Content Ahead of Conor McGregor’s July 11 UFC Return
MMA.INC to leverage one of the biggest attention moments in combat sports to drive original content, user registrations and owned audience growth across MixedMartialArts.com
Apple Raises Prices on Macs, iPads by $200 or More on Some Models
Triller Group (Nasdaq: ILLR) to Acquire Significant SpaceX Position as a Strategic Treasury Asset
Transaction places SpaceX exposure directly on the Company’s balance sheet as a strategic treasury holding
International Association of Campus Law Enforcement Administrators Launches National Campus Drone Readiness Program, Selecting Draganfly to Provide Drone Systems, Services and Training in Alignment with Emerging U.S. Drone Policy
Orlando, FL, June 25, 2026 (GLOBE NEWSWIRE) — Draganfly Inc. (NASDAQ: DPRO; CSE: DPRO; FSE: 3U8) (“Draganfly” or the “Company”), an award-winning Unmanned Systems Developer and capabilities integrator, today announced with the International Association of Campus Law Enforcement Administrators (IACLEA) the launch of the IACLEA national Campus Drone Implementation & Readiness Program for colleges and universities across the United States.
Seegnal to Deploy its Medication Safety Platform Across Nazareth Hospital EMMS, Expanding its Israeli Hospital Footprint
Historic regional trauma center and teaching hospital adopts Seegnal’s patient-specific clinical decision support, expanding the Company’s footprint across Israel’s healthcare system
Cell-based Assays Market Worth USD 46.87 Billion by 2035 | SNS Insider
The U.S. Cell-based Assays Market is projected to grow from USD 3.44 Billion in 2025 to USD 7.31 Billion by 2035, while Europe is expected to expand from USD 5.62 Billion to USD 12.49 Billion, supported by increasing drug discovery activities, biologics research, and adoption of advanced cell-based testing platforms.
XTEND Surpasses $12 Million in Cumulative Defense Orders with $3 Million Follow-On Order Across Two Autonomous System Programs
Follow-On Order Builds on Separate $9 Million Defense Order Announced June 23, 2026, Demonstrates Breadth of XTEND’s Defense Relationships
Nightfood Holdings Signs LOI to Acquire 51% of Jiun Jiang Enterprise
Proposal establishes a platform for semiconductor automation, AI infrastructure, and advanced manufacturing growth
MAIA Biotechnology Completes International Enrollment in Part C of Phase 2 THIO-101 Expansion Trial in Third-Line Non-Small Cell Lung Cancer
Part C domestic enrollment is underway at three clinical sites in the U.S.
Axonex and YAS Collaborate with a Global Insurance Group to Develop Embedded Insurance for Robots Innovative InsurTech Solution Drives AI and Robotics Adoption Across Hong Kong and Southeast Asia
Hong Kong, June 25, 2026 (GLOBE NEWSWIRE) — Mint Incorporation Limited (“Mint” or the “Company”, together with its subsidiaries, the “Group”, NASDAQ: MIMI), a Hong Kong-based company strategically focused on artificial intelligence (AI) and robotics, and an established business interior design and fit-out works provider, today announced that its wholly-owned subsidiary, Axonex Intelligence Limited (“Axonex”), has entered into a collaboration with YAS, Hong Kong’s leading embedded insurance technology company, with underwriting provided by an insurance company under a global insurance group headquartered in Switzerland, to jointly develop an embedded micro-insurance solutions purpose-built for commercial robots, among the first of its kind in Asia. Through this innovative insurance solution, the initiative helps remove a significant barrier to enterprise adoption of AI-powered robots, accelerating the commercial deployment of robotics across Hong Kong and Southeast Asia.
BioRestorative Therapies Announces Completion of BRTX-100 Phase 2 Manufacturing, Highlighting Integrated Regenerative Biologics Platform
MELVILLE, N.Y., June 25, 2026 (GLOBE NEWSWIRE) — BioRestorative Therapies, Inc. (“BioRestorative,” “BRTX,” or the “Company”) (Nasdaq:BRTX), a late-stage clinical regenerative medicine company focused on stem cell-based therapies and products, today announced the successful completion of manufacturing for its BRTX-100 Phase 2 clinical trial, marking a key milestone in the development of its lead cell therapy candidate and underscoring the strength of the Company’s vertically integrated regenerative medicine platform.
Excellere Partners and GHO Capital complete sale of Biocare Medical to Agilent Technologies
Denver, CO and London, UK – 25 June 2026: Excellere Partners (“Excellere”), a Denver-based private equity firm specializing in partnering with entrepreneurs and management teams, and GHO Capital Partners LLP (“GHO”), a specialist investor in global healthcare, today announced the completion of the sale of Biocare Medical (“Biocare”), a global leader in immunohistochemistry (IHC), in situ hybridization (ISH) and fluorescence in situ hybridization (FISH) solutions, to Agilent Technologies, Inc. (“Agilent”, NYSE:A).
M.B.A. Pay Is Drifting Down—and So Is Demand for the Degree
Terra Balcanica Appoints DGWA as European Financial Markets Advisor
Vancouver, British Columbia, June 25, 2026 (GLOBE NEWSWIRE) — Terra Balcanica Resources Corp. (“Terra” or the “Company”) (CSE:TERA; FRA:UB10; OTCQB:TEBAF) is pleased to announce that it has appointed DGWA GmbH (“DGWA”), a Frankfurt-based corporate advisory and capital markets firm, as its European financial markets advisor.
Provectus Biopharmaceuticals Launches Veripure™, an Open Science Program for Medical Research Access to PV-10 (rose bengal sodium)
KNOXVILLE, Tenn., June 25, 2026 (GLOBE NEWSWIRE) — Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT), a clinical-stage biotechnology company developing pharmaceutical grade rose bengal sodium (“RBS”) active pharmaceutical ingredient (“API”) as a platform therapeutic, today announced the launch of its Veripure™ open science research program. Veripure makes PV-10, formulated from pharmaceutical-grade RBS API, freely available to qualified researchers globally without restrictive constraints on study direction, design, or findings. Researchers interested in studying RBS for therapeutic applications through the Veripure program are invited to contact Provectus directly at veripure@pvct.com.
KUSTOM ENTERTAINMENT, INC. ANNOUNCES BINDING AGREEMENT FOR THE DIVESTITURE OF ITS VIDEO SOLUTIONS SEGMENT TO FULLY COMPLETE LIVE ENTERTAINMENT PIVOT
Transaction Structured to Provide Up to $5.5 Million plus 2,000,000 Warrants to acquire shares of common stock of Cycurion, Inc.; Follows Previously Announced Major Live Music Expansion Partnership with Gilley’s Park City
SPIRIT BLOCKCHAIN CAPITAL COMPLETES SHARES FOR SERVICES ISSUANCE
Vancouver, BC, June 25, 2026 (GLOBE NEWSWIRE) — Spirit Blockchain Capital Inc. (CSE: SPIR) (“Spirit” or the “Company”), a Canadian-based publicly listed company focused on blockchain infrastructure and digital asset opportunities, is pleased to announce that it has completed its previously announced shares for services issuance, originally announced on June 18, 2026.
NuCube Energy to Become a Publicly Listed Company Through Business Combination with Launch Two Acquisition Corp.
Idaho Falls, Idaho & Oakland, California, June 25, 2026 (GLOBE NEWSWIRE) — NuCube Energy, Inc. (“NuCube”), an advanced-nuclear technology company productizing factory-built microreactors, and Launch Two Acquisition Corp. (NASDAQ: LPBB) a special purpose acquisition company, (“Launch Two” collectively, the “Parties”), today announced that they have entered into a definitive business combination agreement (the “Transaction” or the “Business Combination”) that would result in NuCube becoming a publicly listed company. Upon closing, the combined company is expected to be listed on Nasdaq or NYSE.
Digital Currency X Technology Enters Into Securities Purchase Agreement for a Private Placement of US$700 Million of Units, Payable in U.S. Dollars or Digital Assets, to Advance Its Digital Asset Treasury Strategy
NEW YORK, June 25, 2026 (GLOBE NEWSWIRE) — Digital Currency X Technology Inc. (Nasdaq: DCX) (“DCX” or the “Company”), a digital asset treasury management company, today announced that it has entered into a securities purchase agreement (the “Agreement”) with certain investors for a private placement of an aggregate of US$700,000,000 of units of the Company (the “Units”). Each Unit consists of one Class A ordinary share, par value US$0.0001 per share (the “Ordinary Share”), and three warrants (the “Warrants”). The purchase price per Unit is US$2.11, and the Warrants have an exercise price of US$2.11 per share (subject to adjustment as set forth in the Warrants), are exercisable on or after June 24, 2026, and will expire three years after such date. The Company intends to use the proceeds from the private placement for working capital and general corporate purposes, including the continued execution of its digital asset treasury strategy and the expansion of its newly established AI cloud computing services business, further diversifying the Company’s revenue base.